Adaptimmune Therapeutics plc (ADAP)

GB — Healthcare Sector
Peers: STOK  FIXX  BDTX  HARP  MREO  PIRS  PDSB  LPTX  AFMD  CRVS  APTO  NKTX  AGIO  PLRX  ACET  INKT  IMGN  SGMO 

Automate Your Wheel Strategy on ADAP

With Tiblio's Option Bot, you can configure your own wheel strategy including ADAP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ADAP
  • Rev/Share 0.1165
  • Book/Share -0.0243
  • PB -1.8754
  • Debt/Equity -0.6224
  • CurrentRatio 2.0167
  • ROIC -0.5852

 

  • MktCap 70418553.0
  • FreeCF/Share -0.0715
  • PFCF -0.6389
  • PE -1.0043
  • Debt/Assets 0.1474
  • DivYield 0
  • ROE -1.8554

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
ADAP
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Cintia Piccina - Chief Commercial Officer Dennis Williams - SVP, Late Stage Development Gavin Wood - CFO John Lunger - VP, Manufacturing Conference Call Participants Marc Frahm - TD Cowen Jonathan Chang - SVB Leerink Arthur He - H.C. Wainwright Graig Suvannavejh - Mizuho Yanan Zhu - Wells Fargo Securities Operator Hello and welcome to Adaptimmune's First Quarter 2025 Business Update Conference Call.

Read More
image for news Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
ADAP
Published: May 07, 2025 by: Newsfile Corp
Sentiment: Neutral

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m.

Read More
image for news Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Adaptimmune Provides Q4 and Full Year 2024 Business Update
ADAP
Published: March 20, 2025 by: Newsfile Corp
Sentiment: Neutral

TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026 Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programs At the end of 2024, Adaptimmune had Total Liquidity 1 of $152 million Evaluating all strategic options to maximize shareholder value Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers …

Read More
image for news Adaptimmune Provides Q4 and Full Year 2024 Business Update

About Adaptimmune Therapeutics plc (ADAP)

  • IPO Date 2015-05-06
  • Website https://www.adaptimmune.com
  • Industry Biotechnology
  • CEO Mr. Adrian G. Rawcliffe
  • Employees 506
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.